news

AstraZeneca awarded damages in Prilosec® patent litigation

Posted: 4 December 2013 | | No comments yet

AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc…

AstraZeneca

AstraZeneca today announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc. (“Apotex”) to pay AstraZeneca approximately $76 million in damages. This ruling is a result of Apotex’s infringing sales of generic omeprazole between 2004 and 2007. This follows a previous ruling in 2007 that found two Prilosec® (omeprazole) formulation patents valid and infringed by Apotex.

AstraZeneca welcomes the court’s ruling.

These damages will not impact Core earnings or AstraZeneca’s full year 2013 financial guidance.

 

Related organisations